|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.16 USD | -0.47% |
|
-8.42% | +21.00% |
| May. 13 | Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating | MT |
| May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Myriad Genetics, Inc. reiterated earnings guidance for the full year 2024. For the year, the company expected revenue to be $820 million to $840 million.
| 1st Jan change | Capi. | |
|---|---|---|
| +21.00% | 2.1B | |
| -4.92% | 12.27B | |
| -5.82% | 7.99B | |
| +5.43% | 5.69B | |
| +26.16% | 5.42B | |
| -9.58% | 4.13B | |
| -59.63% | 2.7B | |
| +8.44% | 2.6B | |
| -3.70% | 2.38B | |
| +0.26% | 1.55B |
MYRIAD GENETICS, INC. 
